2 September 2024 in Annals of Medicine
Human metapneumovirus (HMPV) is a common respiratory pathogen that causes respiratory tract infections. In India, HMPV has been identified as one of the leading causes of morbidity and mortality in infants and young children with respiratory tract infections. The most reported sublineages of HMPV in India are B1, B2, A2b and A2c. A retrospective study was conducted to determine the circulating genotypes of HMPV among SARI cases from January 2016 to December 2018. Positive throat swab samples were confirmed with real-time RT-PCR. Subsequently, these samples were analysed using semi-nested conventional RT-PCR targeting the G gene, followed by sequencing and phylogenetic analysis. Clinical data analysis was also performed using SPSS 15.0 software. All 20 samples from the SARI cases were classified under the A2c sublineage of HMPV. Phylogenetic analysis indicated that these strains were genetically related to those circulating in Japan, China, and Croatia. Among the samples, ten showed 111-nucleotide duplications, while the other ten had 180-nucleotide duplications. Clinical analysis showed that four cases had coinfections with other pathogens. Our extensive analysis of patient samples determined that HMPV, especially the A2c genotype, significantly contributed to SARI cases within our study population, which signifies the importance of considering HMPV as a probable aetiological agent when investigating SARI outbreaks.
13 September 2024 in Acta Tropica
Aedes is the most globally distributed mosquito genus in the 21st century and transmits various arboviral diseases. The rapid expansion of Ae. Aegypti and Ae. albopictus breeding habitats is a significant threat to global public health, driven by temperature and precipitation changes. In this study, bioclimatic variables were employed to predict the spatial distribution of Ae. aegypti and Ae. albopictus in India. The reference coordinate points of (n = 583) Aedes occurrences at a scale of ∼1 km and nineteen bioclimatic factors were retrieved to train SDM (Species Distribution Models) for both species. Maximum entropy modelling was used to predict the species' fundamental climatic niche distributions. Future projections were made using global climate models for 2021-2040 and 2081-2100 separately. The models performed reasonably well (AUC > 0.77). Both species thrived in reduced diurnal temperature and higher annual mean temperatures, with suitability increasing alongside precipitation. Ae. aegypti's projected present and future distribution was broader than that of Ae. Albopictus. The expansion of Aedes suitability varied under different future climatic scenarios. Suitability for Ae. aegypti could expand from between 17.6 and 41.1 % in 2100 under SSP (shared socioeconomic pathways) scenarios 1 and 3, respectively, whereas for Ae. albopictus suitability increased from between 10.2 and 25 % under SSP scenarios 1 and 3 respectively. Preparing for future epidemics and outbreaks requires robust vector distribution models to identify high-risk areas, allocate resources for surveillance and control, and implement prevention strategies.
26 June 2025 in Annals of Medicine
Chikungunya fever is a viral disease spread by Aedes mosquitoes, reported in over 110 countries. In India, it was first detected in Kolkata in 1963 and is now widespread. Diagnosis often relies on detecting anti-chikungunya IgM antibodies, but these may not be present during the acute phase as viremia can last up to 8 days, leading to underreporting. The present study aims to assess the diagnostic use of real-time RT-PCR for detecting chikungunya-specific nucleic acid in serum samples during the early stages of infection. A retrospective cross-sectional study was conducted using archived samples collected as a part of 'the hospital-based Acute Febrile Illness (AFI) surveillance project'. AFI cases having fever ≤8 days and arthralgia without any aetiology between 2016 and 2018 from Karnataka, Kerala, and Tamil Nadu were included in the study. Samples were subjected to nucleic acid extraction followed by chikungunya real-time RT-PCR using a standardized in-house protocol. The samples that tested positive for Chikungunya by real-time RT-PCR were further tested for detecting anti-Chikungunya IgM antibodies using enzyme-linked immunosorbent assay. Demographic characterization of the cases was performed using SPSS version 20 and GraphPad Prism version 10. Out of a total of 646 samples tested, 31 samples (4.79%) were positive by real-time RT-PCR for chikungunya virus, 20 of which had a Ct value of <30, indicating a relatively high viral load. Among the 31 serum samples tested for anti-Chikungunya IgM antibodies, only one showed a positive result. Demographic analysis showed that 67% of cases were male and 32% were female, respectively. Clinical data analysis showed that most of the cases presented with cough (87%), headache (80.6%), myalgia (77.4%), coryza (70.9%), vomiting (58%), and abdominal pain (38.7%). The current study findings highlight the importance of screening patients with fever for up to 8 days and arthralgia for not only detecting IgM antibodies against chikungunya using ELISA but also for chikungunya virus-specific nucleic acid through real-time PCR/nucleic acid amplification techniques, or other methods. Not performing laboratory tests to screen for chikungunya-specific nucleic acid or antigen may result in underreporting of chikungunya cases, thereby impacting effective control measures and management of cases.
1 January 2025 in International Journal of Microbiology
Introduction: Human parainfluenza viruses (HPIVs) are significant causes of respiratory infections, particularly in children, yet their epidemiology remains poorly understood in low‐ and middle‐income countries. HPIVs contribute to 20%–40% of pediatric lower respiratory tract infections (LRTIs) and are a leading cause of croup and hospitalizations. This study was aimed at determining the incidence, distribution, and clinical and laboratory characteristics of HPIV in hospitalized acute febrile illness (AFI) patients. Methods: A total of 12,409 AFI cases from 2016 to 2018 were tested for HPIVs via molecular methods. RNA was extracted from throat swab samples and tested via multiplex real‐time RT‐PCR for HPIV Serotypes 1–4. The demographic, clinical, and laboratory data of HPIV‐positive patients were analyzed statistically. Results: HPIVs were detected in 217 (1.75%) patients, with HPIV‐3 (49.77%) being the most prevalent, followed by HPIV‐4 (18.90%), HPIV‐2 (17.52%), and HPIV‐1 (13.83%). HPIV‐3 exhibited distinct seasonal peaks, mainly affecting children (1–9 years). Significant variations in hematological and biochemical markers were observed among serotypes and age groups. Upper and lower respiratory symptoms, along with gastrointestinal issues and systemic manifestations such as chills, myalgia, and weakness, are commonly reported. Conclusion: HPIVs contribute to respiratory illness across diverse demographics. HPIV‐3 is the predominant serotype, with distinct seasonal and age‐related patterns. Improved surveillance and diagnostics could aid in better management and reduce unnecessary antibiotic use.
9 January 2026 in Critical Public Health
15 September 2026 in Clinical and Experimental Pediatrics
Background: Multisystem inflammatory syndrome in children (MIS-C) is a postinfectious hyperinflammatory condition that can follow a sudden acute respiratory syndrome coronavirus 2 infection. Although several inflammatory markers are used to guide its clinical management, biomarkers that reflect immunomodulatory therapy responses remain limited.Purpose: Evaluate intrapatient changes in serum soluble membrane attack complex/C5b-9 levels before and after immunomodulatory therapy in children with MIS-C.Methods: In this longitudinal observational study, paired serum samples from 100 children diagnosed with MIS-C across 3 tertiary care centers in India were analyzed for soluble C5b-9 (sC5b-9) concentrations before the initiation of immunomodulatory therapy and at clinical recovery. Intrapatient changes were evaluated using paired nonparametric statistical methods. Clinical phenotypes at presentation were documented and explored in relation to baseline sC5b-9 levels.Results: Serum sC5b-9 concentrations significantly declined following immunomodulatory therapy across the cohort (P<0.0001). Elevated pretherapy sC5b-9 levels were observed in patients presenting with shock, multiorgan dysfunction, or cardiac involvement. Although most patients exhibited reduced sC5b-9 levels following therapy, the magnitude of the change varied among individuals, with a subset showing persistently elevated levels at discharge.Conclusion: Serum sC5b-9 levels decreased after immunomodulatory therapy in children with MIS-C, suggesting its potential utility as a longitudinal marker of treatment response. The interpretation of absolute concentrations is limited by the serum-based sampling methodology; however, consistent intrapatient trends support further investigations using optimized complement sampling protocols.